Gary Gregory
President & CEO
NeuroSync, Inc.
118 Washington St, Ste 14
Holliston , MA 01746
United States
(b)(6), (b)(7)(C)FEI 3014133165Issued May 9, 2025Center for Devices and Radiological Health
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3014133165.
Violations10
Issue DateMay 9, 2025
Product TypeMedical Devices
StatusOpen
Letter Details
Firm
NeuroSync, Inc.
Location
Gary Gregory
President & CEO
NeuroSync, Inc.
118 Washington St, Ste 14
Holliston , MA 01746
United States
(b)(6), (b)(7)(C)
FEI Number
3014133165
Country
United States
Issue Date
May 09, 2025
Issuing Office
Center for Devices and Radiological Health
Product Type
Medical Devices
Status
Open
Summary
NeuroSync, Inc. manufactured EYE-SYNC, a virtual reality headset and tablet computer used for eye assessments, but failed to comply with current good manufacturing practice (CGMP) requirements under 21 CFR Part 820. The company did not establish adequate design control procedures to verify that device design outputs met design input requirements, specifically failing to implement required design verification steps outlined in their own Design Controls and Software Design procedures, as evidenced by gaps in their eye tracking performance accuracy documentation. The violations were identified during an FDA inspection conducted from January 6 through February 5, 2025, and the company's February 27, 2025 response was found insufficient to address the inspectional observations.